Literature DB >> 19422797

A novel program to design siRNAs simultaneously effective to highly variable virus genomes.

Hui Sun Lee1, Jeonghyun Ahn, Eun Jung Jun, Sanghwa Yang, Chul Hyun Joo, Yoo Kyum Kim, Heuiran Lee.   

Abstract

A major concern of antiviral therapy using small interfering RNAs (siRNAs) targeting RNA viral genome is high sequence diversity and mutation rate due to genetic instability. To overcome this problem, it is indispensable to design siRNAs targeting highly conserved regions. We thus designed CAPSID (Convenient Application Program for siRNA Design), a novel bioinformatics program to identify siRNAs targeting highly conserved regions within RNA viral genomes. From a set of input RNAs of diverse sequences, CAPSID rapidly searches conserved patterns and suggests highly potent siRNA candidates in a hierarchical manner. To validate the usefulness of this novel program, we investigated the antiviral potency of universal siRNA for various Human enterovirus B (HEB) serotypes. Assessment of antiviral efficacy using Hela cells, clearly demonstrates that HEB-specific siRNAs exhibit protective effects against all HEBs examined. These findings strongly indicate that CAPSID can be applied to select universal antiviral siRNAs against highly divergent viral genomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422797     DOI: 10.1016/j.bbrc.2009.04.143

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Antiviral effects of small interfering RNA simultaneously inducing RNA interference and type 1 interferon in coxsackievirus myocarditis.

Authors:  Jeonghyun Ahn; Ara Ko; Eun Jung Jun; Minah Won; Yoo Kyum Kim; Eun-Seon Ju; Eun Seok Jeon; Heuiran Lee
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

2.  mTOR inhibition as a novel gene therapeutic strategy for diabetic retinopathy.

Authors:  Steven Hyun Seung Lee; Joo Yong Lee; Jun-Sub Choi; Hee Jong Kim; Jin Kim; Seho Cha; Kyoung Jin Lee; Ha-Na Woo; Keerang Park; Heuiran Lee
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

3.  Multispecies-compatible antitumor effects of a cross-species small-interfering RNA against mammalian target of rapamycin.

Authors:  Jeonghyun Ahn; Ha-Na Woo; Ara Ko; Maria Khim; Catherine Kim; Nung Hwa Park; Ho-Young Song; Seong Who Kim; Heuiran Lee
Journal:  Cell Mol Life Sci       Date:  2012-05-05       Impact factor: 9.261

4.  In Vitro Inhibitory Analysis of Rationally Designed siRNAs against MERS-CoV Replication in Huh7 Cells.

Authors:  Sherif Aly El-Kafrawy; Sayed Sartaj Sohrab; Zeenat Mirza; Ahmed M Hassan; Fatima Alsaqaf; Esam Ibraheem Azhar
Journal:  Molecules       Date:  2021-04-29       Impact factor: 4.411

Review 5.  Antiviral RNAi: translating science towards therapeutic success.

Authors:  Priya S Shah; David V Schaffer
Journal:  Pharm Res       Date:  2011-08-09       Impact factor: 4.200

6.  Adeno-Associated Viral Vector-Mediated mTOR Inhibition by Short Hairpin RNA Suppresses Laser-Induced Choroidal Neovascularization.

Authors:  Tae Kwann Park; Si Hyung Lee; Jun Sub Choi; Seung Kwan Nah; Hee Jong Kim; Ha Yan Park; Heuiran Lee; Steven Hyun Seung Lee; Keerang Park
Journal:  Mol Ther Nucleic Acids       Date:  2017-06-01       Impact factor: 8.886

7.  Inhibition of mTOR via an AAV-Delivered shRNA Tested in a Rat OIR Model as a Potential Antiangiogenic Gene Therapy.

Authors:  Steven Hyun Seung Lee; HeeSoon Chang; Ji Hyun Kim; Hee Jong Kim; Jun-Sub Choi; Sunho Chung; Ha-Na Woo; Kyoung Jin Lee; Keerang Park; Joo Yong Lee; Heuiran Lee
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-02-07       Impact factor: 4.799

8.  In Silico Design and Experimental Validation of siRNAs Targeting Conserved Regions of Multiple Hepatitis C Virus Genotypes.

Authors:  Mahmoud ElHefnawi; TaeKyu Kim; Mona A Kamar; Saehong Min; Nafisa M Hassan; Eman El-Ahwany; Heeyoung Kim; Suher Zada; Marwa Amer; Marc P Windisch
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.